Together, these findings position AURKA inhibition as a mechanistically distinct yet convergent approach within the broader MYC–DDR therapeutic landscape, particularly relevant to aggressive brain and neuroendocrine tumours characterised by elevated MYC activity and replication stress. The gene discussed is MYC; the disease is neuroendocrine neoplasm.